Accuracy of Nasal Nitric Oxide Measurement as a Diagnostic Test for Primary Ciliary Dyskinesia. A Systematic Review and Meta-analysis by Shapiro, Adam J. et al.
SYSTEMATIC REVIEW
Accuracy of Nasal Nitric Oxide Measurement as a Diagnostic Test for
Primary Ciliary Dyskinesia
A Systematic Review and Meta-analysis
Adam J. Shapiro1, Maureen Josephson2, Margaret Rosenfeld3, Ozge Yilmaz4, Stephanie D. Davis5, Deepika Polineni6,
Elena Guadagno7, Margaret W. Leigh8 and Valery Lavergne9
1Division of Pediatric Respiratory Medicine, Montreal Children’s Hospital, McGill University Health Centre Research Institute, Montreal,
Quebec, Canada; 2Division of Pediatric Pulmonology, Children’s Hospital of Philadelphia, University of Pennsylvania, Philadelphia,
Pennsylvania; 3Division of Pediatric Pulmonology, Seattle Children’s Hospital and Regional Medical Center, University of Washington,
Seattle, Washington; 4Department of Pediatric Allergy and Pulmonology, Faculty of Medicine, Celal Bayar University, Manisa,
Turkey; 5Section of Pediatric Pulmonology, Allergy and Sleep Medicine, Department of Pediatrics, Riley Children’s Hospital, Indiana
University School of Medicine, Indianapolis, Indiana; 6Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine,
University of Kansas, Kansas City, Kansas; 7Medical Library, McConnell Resource Center, McGill University Health Centre, Montreal,
Quebec, Canada; 8Division of Pediatric Pulmonology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill,
North Carolina; and 9Department of Medical Biology, Sacre´-Coeur Hospital, University of Montreal, Montreal, Quebec, Canada
Abstract
Rationale: Primary ciliary dyskinesia (PCD) is a rare disorder
causing chronic otosinopulmonary disease, generally diagnosed
through evaluationof respiratory ciliaryultrastructure and/or genetic
testing. Nasal nitric oxide (nNO) measurement is used as a PCD
screening test because patients with PCDhave low nNO levels, but its
value as a diagnostic test remains unknown.
Objectives: To perform a systematic review to assess the utility
of nNO measurement (index test) as a diagnostic tool compared
with the reference standard of electron microscopy (EM)
evaluation of ciliary defects and/or detection of biallelic mutations
in PCD genes.
Data Sources: Ten databases were searched for reference sources
from database inception through July 29, 2016.
Data Extraction: Study inclusion was limited to publications with
rigorous nNO index testing, reference standard diagnostic testing
with EM and/or genetics, and calculable diagnostic accuracy
information for cooperative patients (generally.5 yr old) with high
suspicion of PCD.
Synthesis:Meta-analysis provided a summary estimate for
sensitivity and specificity and a hierarchical summary receiver
operating characteristic curve. TheQuality Assessment ofDiagnostic
Accuracy Studies-2 toolwas used to assess study quality, andGrading
ofRecommendationsAssessment, Development, andEvaluationwas
used to assess the certainty of evidence. In 12 study populations
(1,344 patients comprising 514 with PCD and 830 without PCD),
using a reference standard of EM alone or EM and/or genetic testing,
summary sensitivity was 97.6% (92.7–99.2) and specificity was 96.0%
(87.9–98.7), with a positive likelihood ratio of 24.3 (7.6–76.9), a
negative likelihood ratio of 0.03 (0.01–0.08), and a diagnostic odds
ratio of 956.8 (141.2–6481.5) for nNO measurements. After
studies using EM alone as the reference standard were excluded,
the seven studies using an extended reference standard of EM
and/or genetic testing showed a summary sensitivity of nNO
measurements of 96.3% (88.7–98.9) and specificity of 96.4%
(85.1–99.2), with a positive likelihood ratio of 26.5 (5.9–119.1), a
negative likelihood ratio of 0.04 (0.01–0.12), and a diagnostic odds
ratio of 699.3 (67.4–7256.0). Certainty of the evidence was graded as
moderate.
Conclusions: nNO is a sensitive and specific test for PCD in
cooperative patients (generally.5 yr old)withhigh clinical suspicion
for this disease.With amoderate level of evidence, this meta-analysis
confirms that nNO testing using velum closure maneuvers has
diagnostic accuracy similar to EM and/or genetic testing for PCD
when cystic fibrosis is ruled out. Thus, low nNO values accompanied
by an appropriate clinical phenotype could be used as a diagnostic
PCD test, though EM and/or genetics will continue to provide
confirmatory information.
Keywords: primary ciliary dyskinesia; Kartagener syndrome;
nitric oxide
(Received in original form January 23, 2017; accepted in final form May 5, 2017 )
Ann Am Thorac Soc Vol 14, No 7, pp 1184–1196, Jul 2017
Copyright © 2017 by the American Thoracic Society
DOI: 10.1513/AnnalsATS.201701-062SR
Internet address: www.atsjournals.org
1184 AnnalsATS Volume 14 Number 7| July 2017
Primary ciliary dyskinesia (PCD) is a rare
autosomal recessive disease resulting in
impaired mucociliary clearance and chronic
otosinopulmonary infections. Nasal nitric
oxide (nNO) levels are low in PCD, and
because nNO results are immediately available,
these measurements are often used as a
screening tool for PCD before proceeding to
ciliary electron microscopy (EM), high-speed
videomicroscopic analysis (HSVA), or genetic
analysis for confirmatory diagnostic testing.
These latter tests are expensive (U.S.$550–
U.S.$2,200), can take months to complete,
and sometimes yield nondiagnostic results.
Inexperience in obtaining biopsy samples can
lead to insufficient cilia for EM analysis, and
inexperience in interpretation can lead to
false-positive or false-negative EM results.
Diagnostic HSVA testing can be challenging
because (1) there is no standardization of
ciliary waveform analysis, (2) multiple biopsies
at separate visits or re-differentiation of
ciliated cells in culture is required to ensure
permanence of diagnostic ciliary waveform
abnormalities (i.e., not arising from secondary
insults such as viral infection) (1), and (3)
interpretation of HSVA samples from
healthy control subjects shows poor
interobserver agreement (2). Finally,
genetic testing currently can detect biallelic
mutations in only about two-thirds of
patients with PCD (3).
Previous researchers have examined the
diagnostic testing accuracy of nNO in
PCD, but many of them incorporated
methodological flaws in their study design,
which could affect diagnostic accuracy. These
errors included using HSVA as a screening
test for study entry (excluding all subjects
with normal videomicroscopy from
further PCD testing), incorporating nNO
measurement into both index (the new test
being evaluated) and reference (the chosen
gold standard) standard testing (4, 5), or
using imperfect reference standard testing by
enrolling some subjects diagnosed with PCD
through HSVA analysis alone and not
presenting data on permanence of ciliary
waveform abnormalities based on repeat
HSVA testing or after cellular regrowth (6).
Authors of two previous meta-analyses
examined the diagnostic testing accuracy of
nNO in PCD, but these analyses included
studies with methodological flaws (7, 8).
These methodological errors included (1)
not providing detailed information on tests
used to diagnose patients with PCD (9–11);
(2) inclusion of nonstandard EM diagnoses
in the reference standard (isolated inner
dynein arm [IDA] defects without
microtubule disorganization [MTD] and
without repeat verification of isolated IDA
defects based on two separate biopsies)
(12, 13); (3) inclusion of patients with cystic
fibrosis (CF) as disease control subjects, in
whom nNO levels commonly fall below
PCD cutoff values, impacting diagnostic
accuracy (14–17); and (4) using nonstandard
technology or techniques for nNO
measurement (6, 10, 16). Additionally, these
meta-analyses did not routinely incorporate
genetic results into their reference standard,
even though commercial genetic testing is
now a frontline clinical test for PCD.
The American Thoracic Society has
supported creation of clinical diagnostic
guidelines for PCD. As part of these
guidelines, a robust systematic review and
meta-analysis was performed to examine
the diagnostic testing accuracy of nNO
measurement for PCD, and the results are
presented here. This review uses strict
inclusion and exclusion criteria to define
acceptable index and reference standard
testing for PCD. The objective of this
analysis was to assess if nNO measurement
can be used as a diagnostic test for PCD
(as opposed to only a screening test) in
cooperative patients (generally .5 yr old)
who have a high probability of having this
disease based on a highly suggestive clinical
phenotype (18) and in whom CF has been
ruled out. Specifically, the usefulness of this
tool is evaluated as a replacement for the
diagnostic reference standards of classic EM
ultrastructural ciliary defect and/or biallelic
causative mutations in PCD genes.
Methods
Data Sources and Searches
For the literature search, we consulted the
following consulted databases: Africa-Wide
Information (EBSCOhost, Ipswich, MA),
AMED Allied and Complementary
Medicine (Ovid; Wolters Kluwer Health,
New York, NY), BIOSIS (Ovid), The
Cochrane Library (John Wiley & Sons,
Hoboken, NJ), Embase (Ovid), Global
Health (Ovid), MEDLINE (Ovid), PubMed
(National Library of Medicine, National
Institutes of Health, Bethesda, MD), Scopus
(Elsevier, Amsterdam, the Netherlands),
and Web of Science (Thomson Reuters,
New York, NY). We manually searched
all references in the included articles to
identify other potential literature of interest.
The search was performed starting from
all database inceptions until July 29, 2016
(see Appendix E1 in the online supplement).
Study Selection
Eligible studies. Selected studies evaluate the
accuracy of nNO testing (index test) in
cooperative patients (generally .5 yr old),
who were deemed to have a high
probability of having PCD on the basis of a
compatible clinical phenotype compared
with the reference standards of classic EM
ultrastructural ciliary defect (outer dynein
arm defect, outer dynein arm defect plus
IDA defect, IDA defect with MTD, radial
spoke or central apparatus defect) and/or
biallelic mutations in known PCD genes.
Articles were not excluded on the basis of
language or date of publication.
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Exclusion criteria. Articles were
excluded if any of the following were
present:
1. Fewer than 10 patients with PCD were
included in the recruited population;
2. The index test was inadequate because
nNO measurement used
electrochemical technology (NIOX
MINO; Circassia, Uppsala, Sweden),
used only nonvelum closure techniques
(tidal breathing), and/or used nasal
sampling flow rates outside the
American Thoracic Society/European
Respiratory Society recommended
range (19);
3. The reference standard relied on only a
single HSVA for PCD confirmation
(without a second positive PCD
diagnostic test or without HSVA after
cellular regrowth in culture) or at least
30% of subjects had nonstandard EM
defects (unrepeated, isolated IDA
defects without MTD) (20);
4. Diagnostic testing accuracy was either
not provided, not accurate, or not
calculable; and/or
5. Index testing was incorporated into the
reference standard.
Selection process. After duplicate
article exclusion, two independent reviewers
(A.J.S., D.P.) screened titles and abstracts to
exclude nonpertinent publications. Full
texts of eligible articles were assessed
for final eligibility by a team of three
independent reviewers (M.J., M.R., O.Y.).
Final selection was based on full-text
assessment with complementary
information provided by authors when
needed. Three months were allowed for
authors to answer e-mail queries, after
which articles lacking crucial information
were excluded. If the article was included but
was found to contain missing information,
a worst-case scenario was assumed (e.g.,
for unconfirmed, isolated IDA defects,
patients were assumed not to have PCD).
Disagreements were resolved by discussion
(A.J.S., V.L.).
Data Abstraction
Two reviewers extracted data independently
(A.J.S. and M.J., M.R., or O.Y.) and assessed
data quality (A.J.S. and V.L.). Disagreements
were resolved through discussion with a
third reviewer (M.J.). nNO values derived by
exhalation against resistance (ER) and
breath-holding (BH) techniques were
collected; BH values were accepted if ER
data were unavailable. If nNO measurement
techniques were unclear, authors were
contacted for clarification on techniques
used and the number of subjects who
performed ER or BH maneuvers. All nNO
measurement data are presented in
nanoliters per minute. Quality assessment
data were collected, including blinding to
reference or index tests, prespecification of
the PCD diagnostic nNO cutoff value, and
index test results as compared with the
reference standard (true-positive, false-
positive, true-negative, false-negative, and
inconclusive result).
Quality Assessment
The Quality Assessment of Diagnostic
Accuracy Studies-2 tool was used to evaluate
the internal and external validity of each
study (21). Risk of bias and applicability
were assessed in four domains (patient
selection, index test, reference standard,
and flow/timing). Each item was graded as
low, high, or unclear risk. The Grading
of Recommendations Assessment,
Development, and Evaluation system for
diagnostic test accuracy (22–24) was used
to analyze the certainty of evidence for each
test result and for overall accuracy. In
assessing the certainty of evidence, we
considered the study design, risk of bias,
precision, consistency, and directness.
Data Synthesis and Analysis
A bivariate model was used to calculate
summary estimates for sensitivity and
specificity with a generalized linear mixed
model approach. Summary likelihood ratios
and diagnostic odds ratios were reported.
Good discrimination was defined as a
positive likelihood ratio greater than 5.0 and
Records identified through
database searching
(n = 10,787)
Additional records identified
through other sources
(n = 0)
Records after duplicates
removed
(n = 6,204)
Records screened
(n = 6,204)
Full-text articles assessed
for eligibility
(n = 76)
Studies included in
quantitative synthesis
(meta-analysis)
(n = 11)
Full-text articles excluded
(n = 65)
-  No PCD subjects (18)
-  <10 subjects (2)
-  Not related to nNo (3)
-  Exhaled NO only (13)
-  Non-chemiluminescence (2)
-  Aberrant nNO sampling method (2)
-  No data on sensitivity/specificity (14)
-  Index test in reference standard (3)
-  Duplicate data (3)
-  Review article (3)
-  Meta-analysis (2)
Records excluded
(n = 6,128)
-  Non-human subjects (537)
-  Non-motile cilia (229)
-  Not cilia related (376)
-  Motile cilia, not PCD (516)
-  PCD, but not nNO related (555)
-  Review (1139)
-  Textbook (125)
-  Conference proceedings (362)
-  Editorials, letters, meetings (528)
-  Case reports (1128)
-  Other (243)
Figure 1. Summary of evidence search and selection. nNO= nasal nitric oxide; NO = nitric oxide; PCD = primary ciliary dyskinesia.
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Table 1. Study and patient characteristics
Study Author,
Year
(Reference)
Location Study
Design
Total Patients* (n) Patient Description Prevalence of
Patients with
PCD (n)
Age Male Sex
(n [%])
Beydon et al.,
2015 (29)
France Cohort 86 patients suspected
of having PCD
Patients included children with
chronic rhinosinusitis,
serous otitis media,
bronchiectasis, chronic
bronchitis, or situs inversus.
49 PCD total;
only 44 PCD
performed
nNO test
correctly
PCD median = 11.4 yr
(range, 7–13.9)
81 of 142
(57.0%)
49 of 86 (57.0%) Non-PCD median =
7.9 yr (range, 4.9–
11.6)
Boon et al.,
2014 (14)
Belgium Case–control 191 patients total Patients with PCD included
children and adults with
recurrent upper or lower
respiratory tract infections
with or without organ situs
anomalies.
38 (NA) Range = 5–25 yr 85 of 191
(44.5%)38 PCD PCD = 14.3 yr (range,
8.8–18.1)
153 non-PCD
(51 HC, 48 asthma,
54 humoral
immunodeficiency)
Non-PCD HC =
14.9 yr (range, 10.8–
20.4), asthma =
12.1 yr (range, 9.8–
16.5), humoral
immunodeficiency=
10.7 yr (range,
8.2–15.6)
Harris et al.,
2014 (16)
United
Kingdom
Case–control 44 patients Unclear 13 (NA) Range = 6–79 yr Not given
13 PCD
31 non-PCD (16 with
symptoms, 15 HC)
Leigh et al.,
2013 (17)
(leading site)
United
States
Case–control 296 patients Patients with PCD included
children and adults with
respiratory features
suggestive of PCD
(unexplained neonatal
respiratory distress, year-
round nasal congestion,
year-round wet cough, more
than five episodes of otitis
media by age 2 yr, or situs
anomalies, usually after
cystic fibrosis and
immunodeficiency excluded.
149 (NA) PCD mean = 19.16
14.8 yr
139 of 296
(47.0%)
149 PCD Non-PCD HC mean =
20.9615.7 yr,
asthma = 14.86
11.5 yr, COPD =
61.16 8.9 yr
147 non-PCD (37
asthma, 32 COPD,
78 HC)
Leigh et al.,
2013 (17)
(other sites)
United
States
Cohort 155 patients suspected
of having PCD
Patients included children and
adults with respiratory
features suggestive of PCD
(unexplained neonatal
respiratory distress, year-
round nasal congestion,
year-round wet cough, more
than five episodes of otitis
media by age 2 yr, or situs
anomalies, usually after
cystic fibrosis and
immunodeficiencies
excluded.
71 of 155
(45.8%)
PCD mean = 23.36
18 yr
64 of 155
(41.3%)
Non-PCD mean =
31.86 22.3 yr
Mateos-Corral
et al.,
2011 (15)
Canada Case–control 53 patients Patients with PCD included
children with sinopulmonary
symptoms typical of PCD,
with CF and
immunodeficiency ruled out.
20 (NA) PCD mean = 11.46
3.5 yr
26 of 53
(49.1%)
20 PCD Bronchiectasis
mean = 10.96
3.3 yr, HC mean =
11.06 3.7 yr
33 non-PCD (14
bronchiectasis, 19
HC)
Noone et al.,
2004 (30)
United
States
Case–control 140 patients Patients with PCD included
children and adults with
lower airway disease with
productive cough, wheeze,
or shortness of breath and
chronic upper airway
symptoms of rhinitis/
sinusitis with or without situs
inversus totalis.
69 (NA) Children with PCD
median = 8 yr
(range, 1–17)
PCD: 36
of 78
(46.2%)
69 PCD Adults with PCD
median = 36 yr
(range, 19–73)
71 non-PCD (27 HC,
44 healthy
heterozygotes)
Non-PCD HC mean =
376 2 yr, healthy
heterozygotes =
446 2 yr
Papon et al.,
2012 (31)
France Cohort 34 patients
suspected of having
PCD
Patients included children and
adults with chronic upper
and/or lower respiratory
tract infections, bronchitis,
bronchiectasis, and
sinusitis.
13 of 34
(38.2%)
Mean = 32.5 yr (range,
10–72)
16 of 34
(47.1%)
(Continued)
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a negative likelihood ratio less than 0.2 (25).
A hierarchical summary receiver operating
characteristic curve was constructed to
describe the relationship between a
continuous cutoff and accuracy. Analyses
were performed using Stata version IC 14
software (StataCorp, College Station, TX)
with the commands “metandi” and
“metandiplot” (26). Different sources of
heterogeneity other than variation in
thresholds between studies were explored.
A sensitivity analysis was performed to
estimate the accuracy of nNO testing after
excluding studies relying on EM alone
as a reference standard. Other sources
of heterogeneity were explored using
subgroup analyses. Analyses were
performed in Review Manager 5.3 (The
Cochrane Collaboration, London, UK).
Heterogeneity was assessed by visual
inspection of the summary receiver
operating characteristic curve.
General Methodology
This article follows the Preferred Reporting
Items for Systematic Review and Meta-
Analysis Protocols guidelines for systematic
reviews and meta-analyses (Appendix E2)
(27) and the Cochrane Handbook for DTA
Reviews recommendations (28).
Results
Study Selection
In total, 10,787 records were identified
through a generalized search of all
publications related to PCD for use in
comprehensive guidelines on PCD
diagnosis. Results were not initially limited
to articles investigating nNO testing. After
removing duplicates, 6,204 records were
screened by title and abstract, and 6,127
records not addressing nNO testing were
excluded. Seventy-six full-text articles
were assessed for eligibility, 65 of which
were excluded (Figure 1). Twelve study
populations from 11 articles were
included in the quantitative synthesis
(14–17, 29–35).
Study Characteristics
All 12 included studies were published
between 2003 and 2015, representing the
following countries: Italy (n = 3), United
States (n = 3), France (n = 2), the United
Kingdom (n = 2), Belgium (n = 1), and
Canada (n = 1). Sample sizes ranged from
28 to 373 patients (8–149 patients with
PCD, 15–153 patients without PCD). Four
studies used cohort designs (prospective
investigation of consecutive symptomatic
referrals for PCD), and eight studies used
case–control designs (retrospective
comparison of previously diagnosed PCD
populations with healthy and/or disease
control subjects).
Population Characteristics
A total of 1,721 patients were included in
these 12 studies (Table 1). In two studies,
42 patients were excluded for technical
difficulties (problems with the NO analyzer,
nasal obstruction, high ambient NO, or
incomplete data) (29, 33). We excluded 191
patients with CF (14–17, 30, 34) to better
reflect real-world practice, where CF should
be ruled out before nNO testing for PCD, as
well as 88 uncooperative children who
could not perform nNO with velum closure
techniques (32, 33). We further excluded
Table 1. (Continued )
Study Author,
Year
(Reference)
Location Study
Design
Total Patients* (n) Patient Description Prevalence of
Patients with
PCD (n)
Age Male Sex
(n [%])
Piacentini et al.,
2008 (32)
Italy Case–control 35 patients Patients with PCD included
children with situs inversus
and/or bronchiectasis and/
or sinusitis.
10 PCD total;
only 8
performed
nNO test
correctly (NA)
PCD mean = 17 yr 53 of 87
(60.9%)8 PCD Non-PCD = 27 school
aged, mean age 7 yr
27 non-PCD (HC)
Pifferi et al.,
2011 (33)
Italy Cohort 173 patients suspected
of having PCD
Patients included children with
clinical history and
symptoms of PCD, without
cystic fibrosis, aspiration,
gastroesophageal reflux, or
immunodeficiency.
48 PCD total;
only 40 PCD
performed
nNO test
correctly
Median = 6.2 yr
(range, 1 mo–17.5
yr)
105 of 209
(50.2%)
48 of 173
(27.7%)
Santamaria
et al.,
2008 (35)
Italy Case–control 28 patients Unclear 14 (NA) PCD mean = 15 yr
(range, 7–27)
18 of 28
(64.3%)
14 PCD HC mean = 16 yr
(range, 7–27)
14 non-PCD (14 HC)
Wodehouse
et al.,
2003 (34)
United
Kingdom
Case–control 108 patients Unclear 42 (NA) PCD mean = 34.26
10.9 yr
48 of 108
(44.4%)
42 PCD Non-PCD range of
means = 36.2–53.2
yr
66 non-PCD (20
bronchiectasis, 12
Young’s syndrome,
18 sinusitis, 16 HC)
Definition of abbreviations: CF = cystic fibrosis; COPD = chronic obstructive pulmonary disease; HC = healthy control subjects; NA = not applicable;
nNO= nasal nitric oxide; PCD = primary ciliary dyskinesia.
*Number of patients included in our final analysis after excluding patients experiencing technical difficulties with nNO testing (Beydon and colleagues [29;
n = 39] and Pifferi and colleagues [33; n = 3]), subjects with CF (Boon and colleagues [14; n = 50], Harris and colleagues [16; n = 6], Leigh and colleagues
[17; lead site, n = 77], Mateos-Corral and colleagues [15; n = 32], Noone and colleagues [30; n = 11], and Wodehouse and colleagues [34; n = 15]),
and patients with an inconclusive reference standard result (Beydon and colleagues [29; n = 56]). Additionally, uncooperative children who could perform
only tidal breathing nNO measurements were excluded from the analysis (Beydon and colleagues [29; PCD, n = 5; non-PCD, n = 7], Piacentini and
colleagues [32; PCD, n = 2; healthy control subjects, n = 50], and Pifferi and colleagues [33; PCD, n = 8; non-PCD, n = 28]).
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Table 2. Index test and reference standard characteristics
Study
Authors, Year
(Reference)
Index Test Characteristics* Reference Standard Characteristics*
Analyzer Flow Rate
(L/Min)
Method Cutoff
(nl/Min)
PCD Diagnosis EM Ultrastructure Genetics PCD Diagnosis
Not Confirmed
by EM and/or
Genetics
Beydon et al.,
2015† (29)
NIOX Flex,
Endono
8000
0.30 Mainly ER, 5
PCD via
TB were
excluded
82.2 44 of 49 PCD
analyzed: EM
(n = 44) and/or
genetics (n = 22)
ODA (n = 17) DNAI1 (n = 5) Three IDA defects
alone without
confirmation by
genetics (6.8%)
ODA1IDA (n = 5) DNAI2 (n = 1)
Central pair (n = 10) RSPH1 (n = 1)
RSPH9 (n = 1)
RSPH4A (n = 2)
DYX1C1 (n = 2)
RPGR (n = 1)
Unknown total
number of genes
tested
IDA1MTD (n = 9) CCDC39 (n = 6)
CCDC40 (n = 3)
Unknown total
number of genes
tested
IDA alone (n = 3)
Boon et al.,
2014† (14)
Eco Physics
CLD88
0.30 ER 90 38 PCD analyzed:
EM (n = 23) or
HSVA after
ciliary culture
regrowth (n =
15), and/or post
hoc confirmation
by genetics
(n = 21)
ODA (n = 19) DNAH5 (n = 4) Two normal EM
without
confirmation by
genetics (5.1%)
Only DNAH5 tested
IDA1MTD (n = 3) CCDC40 (n = 3)
Only CCDC40 tested
RSP (n = 1) RSPH4 (n = 1)
Unknown total
number of genes
tested
Normal EM with
abnormal HSVA
(n = 15)
DNAH11 (n = 10)
Exome sequence
used for 10 cases
HYDIN (n = 2)
CCDC65 (n = 1)
Unknown total
number of genes
tested
Harris et al.,
2014† (16)
NIOX Flex 0.30 BH 38 13 PCD analyzed:
EM (n = 11) or
HSVA after
ciliary culture
regrowth in
some cases with
post hoc
confirmation by
genetics (n = 2)
ODA (n = 5) 0
ODA1IDA (n = 5)
IDA1MTD (n = 1)
Normal EM with
abnormal HSVA
(n = 2)
DNAH11 (n = 2)
Only DNAH11 tested
Leigh et al.,
2013† (17)
(leading site)
Sievers 280i,
Eco Physics
CLD88,
NIOX Flex
0.50, 0.33,
0.30
ER 76.9 149 PCD analyzed:
EM (n = 143) or
genetics (n = 6)
ODA (n = 87) 0
ODA1IDA (n = 28)
IDA1MTD (n = 23)
CA (n = 5)
Normal EM (n = 6) DNAH11 (n = 6)
Leigh et al.,
2013† (17)
(other sites)
Sievers 280i,
Eco Physics
CLD88,
NIOX Flex
0.50, 0.33,
0.30
ER 76.9 71 PCD analyzed:
EM (n = 65) or
genetics (n = 6)
ODA (n = 36) 0
ODA1IDA (n = 13)
IDA1MTD (n = 15)
CA (n = 1)
Normal EM (n = 3) Confirmed but not
disclosed (n = 6)
Inadequate EM
(n = 3)
Unknown total
number of genes
tested
Mateos-Corral et
al., 2011 (15)
Eco Physics
CLD88
0.33 ER 58.5 20 PCD analyzed:
EM (n = 20)
with post hoc
confirmation by
genetics (n = 17)
ODA1IDA (n = 11) DNAH5 (n = 6) 0
IDA1MTD (n = 4) DNAH11 (n = 1)
ODA (n = 3) DNAI2 (n = 1)
RSP (n = 2) CCDC39 (n = 2)
CCDC40 (n = 1)
DYX1C1 (n = 3)
RSHP4A (n = 1)
KTU (n = 1)
LRRC50 (n = 1)
Two-gene panel
used in one case
12-gene panel used
in 12 cases
21-gene panel used
in three cases
32-gene panel used
in four cases
(Continued)
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56 patients who had inconclusive reference
standard results (29). In total, 1,344
patients were analyzed (514 patients with
PCD, 830 patients without PCD). Half of
the studies included mainly a pediatric
population (,18–25 years old) (14, 15, 29,
32, 33, 35), and half included patients of all
ages (16, 17, 30, 31, 34). The prevalence of
patients with PCD in cohort studies ranged
from 28 to 57% of patients included in the
quantitative analyses (17, 29, 31, 33). Nine
studies provided information on symptoms
leading to clinical suspicion of PCD, which
generally included at least one of the
following: chronic rhinosinusitis, chronic
otitis media, chronic bronchitis,
bronchiectasis, neonatal respiratory
distress, and/or organ laterality defects
(mainly situs inversus totalis). CF was ruled
out in six studies, and immunodeficiency
was ruled out in five studies, prior to PCD
testing.
Index Test Characteristics
Several different brands of
chemiluminescence NO analyzers were used
across the studies (NIOX Flex [Circassia],
Endono 8000 [SERES Environment, Aix-en-
Provence, France], CLD88 [Eco Physics,
Du¨rnten, Switzerland], Sievers 280i [GE
Analytical Instruments, Boulder, CO], EVA
4000 [Hewlett Packard Enterprise, Palo
Alto, CA], LR2000 [Rochester, UK])
(Table 2). Sampling flow rates ranged from
0.25 to 0.5 L/min, but only one study
included regular verification (via standard
operating procedures) of sampling flow
rates with direct measurement using a
Gilmont flowmeter (Cole-Parmer, Vernon
Hills, IL) (17). In most studies, researchers
performed device calibration according
to the device manufacturer’s
recommendations. In six studies,
researchers reported nNO measurement via
ER; in five studies, researchers used BH
maneuvers; and the technique used was not
fully reported in one study. Diagnostic nNO
cutoff values ranged from 16.8 to 100 nl/min,
with a median cutoff at 76.9 nl/min.
Reference Standards Characteristics
and Strategies
Electronic microscopy. All studies included
ciliary EM as the sole or main reference
standard (Table 2). The majority followed
standard EM methodology (36). Most
isolated IDA defects were either confirmed
upon repeat EM study, associated with
MTD on post hoc EM review, or confirmed
Table 2. (Continued )
Study
Authors, Year
(Reference)
Index Test Characteristics* Reference Standard Characteristics*
Analyzer Flow Rate
(L/Min)
Method Cutoff
(nl/Min)
PCD Diagnosis EM Ultrastructure Genetics PCD Diagnosis
Not Confirmed
by EM and/or
Genetics
Noone et al.,
2004† (30)
Sievers 270B 0.50 BH 100 69 PCD analyzed:
EM (n = 60) or
complete clinical
phenotype with
post hoc
confirmation by
genetics (n = 9)
ODA (n = 31) Confirmed but not
disclosed (n = 9)
0
ODA1IDA (n = 16) Only two genes
tested
IDA1MTD (n = 13)
Papon et al.,
2012 (31)
EVA4000 Per ATS
standards
Per ATS
standards
100 13 PCD analyzed:
EM (n = 13)
ODA (n = 9) 0
IDA1nexin link (n = 2)
ODA1IDA (n = 1)
Central pair (n = 1)
Piacentini et al.,
2008 (32)
NIOX Flex 0.30 Mainly BH, 2
PCD via
TB were
excluded
20.4 8 of 10 PCD
analyzed: EM
(n = 10)
ODA1IDA (n = 7) 0
ODA (n = 1)
IDA (n = 2)
Pifferi et al.,
2011† (33)
Eco Physics
CLD88
0.33 Mainly ER, 8
PCD via TB
were
excluded
96 40 of 48 PCD
analyzed: EM
(n = 42) or HSVA
after ciliary
culture regrowth
with post hoc
confirmation by
genetics (n = 6)
ODA1IDA (n = 23) 0
IDA1CA1MTD
(n = 12)
ODA (n = 2)
IDA1MTD (n = 3)
IDA (n = 2)
Normal EM with
abnormal HSVA
(n = 6)
DNAH11 (n = 6)
Only DNAH11 tested
Santamaria et al.,
2008 (35)
NIOX Flex 0.28 BH 16.8 14 PCD analyzed:
EM (n = 14)
ODA1IDA (n = 8) One nonclassic EM
anomaly without
confirmation by
genetics (7.1%)
ODA (n = 1)
IDA1MTD (n = 3)
Central pair (n = 1)
Basal body anomaly
(n = 1)
Wodehouse et al.,
2003 (34)
LR2000 0.25 BH 50 42 PCD analyzed:
EM (n = 42)
ODA (n = 21) 12 IDA defects
alone without
confirmation by
genetics (28.6%)
ODA1IDA (n = 5)
Transposition (n = 2)
Radial spoke (n = 2)
Unspecified IDA
(n = 12)
Definition of abbreviations: ATS = American Thoracic Society; BH = breath hold; CA = central apparatus defect; EM = electron microscopy; ER = exhalation
against resistance; HSVA= high-speed videomicroscopic analysis; IDA1MTD= inner dynein arm and microtubule disorganization defect; ODA = outer dynein
arm defect; ODA1IDA = outer dynein arm and inner dynein arm defect; PCD =primary ciliary dyskinesia; RSP= radial spoke defect; TB= tidal breathing.
*All information in italics is derived from personal communications with the studies’ authors.
†Studies considered as using a combination of EM and/or genetics as the reference standard.
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post hoc by disease-causing mutations in
CCDC39 or CCDC40 genes. Nevertheless,
Wodehouse and colleagues reported
12 patients (28.6%) as having isolated IDA
defects without further specification by the
authors, which increased the level of bias
for this included publication (34). One
basal body anomaly reported as PCD was
excluded from analysis (35).
Genetic testing. Researchers in three
studies reported genetic testing as part of the
original reference standard (usually as a
complementary tool when EM was
nondiagnostic rather than as a systematic
test used with all patients) (17, 29). After
contacting authors, we found five
additional cohorts (14–16, 30, 33) in which
genetic testing was performed post hoc for
individuals with EM defects (n = 24) or
nondiagnostic EM studies (n = 32). In two
cohorts, only a single PCD gene (DNAH11)
was tested; in one cohort, two PCD genes
were tested; in one cohort, at least six PCD
genes were tested; and in one cohort, 12–32
PCD genes were tested (Table 2). In the
meta-analysis, patients with biallelic
mutations in a PCD-causing gene, whether
identified prospectively or post hoc, were
categorized as having PCD.
Quality Assessment
Patient selection (risk of bias and
applicability). Four studies had a cohort-
type design (17, 29, 31, 33), whereas eight
were case–control studies (Figure 2).
Among the case–control studies, five used
disease control subjects (14–17, 34) and
three used healthy control subjects (17, 30,
32, 35). The populations examined in the
cohort studies were selected populations
considered at high risk for PCD (excluding
patients with CF) in whom PCD testing was
being pursued.
Index test (risk of bias and
applicability). In 7 of 12 studies, the
nNO cutoff was not prespecified. Blinding
of the index test was often not reported,
but because nNO is an objective
measurement, this was judged as having low
impact on the risk of bias. In most studies,
patients were tested when free of acute
respiratory tract infection for more
than 2 weeks and not around nasal
instrumentation. Only nNO results from
cooperative children who could perform
velum closure maneuvers (via BH or ER
techniques) were evaluated.
Reference standard (risk of bias and
applicability). The majority of studies
FLOW AND TIMING
REFERENCE STANDARD
INDEX TEST
PATIENT SELECTION
80%60%
Proportion of studies with low, high or unclear
RISK of BIAS
40%20%0% 100% 80%60%
Proportion of studies with low, high, or unclear
CONCERNS regarding APPLICABILITY
40%20%0% 100%
Low High Unclear
Flow and
timing
Reference
standard
Beydon 2015
Risk of bias Applicability
Boon 2014
Harris 2014
Leigh 2013 (leading site)
Leigh 2013 (other sites)
Mateos Coral 2011
Noone 2004
Papon 2012
Piacentini 2008
Pfierri 2011
Santamaria 2008
Wodehouse 2003
Patient
selection
Index
test
Low LowHigh Unclear
Unclear UnclearLow Low
Unclear UnclearHigh Low
Unclear UnclearUnclear Low
Low LowLow Low
Unclear UnclearHigh Low
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Unclear UnclearHigh High
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Figure 2. Assessment of validity of individual studies with Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 tool for the 12 included
studies. The QUADAS-2 tool is designed to assess the quality of primary diagnostic accuracy studies and consists of four key domains evaluating
the methods used in regard to patient selection, index test, reference standard, and flow of patients through the study, as well as timing of the index
test and reference standard. The results presented show several studies with high risk of bias with regard to the index test domain, especially in
case–control studies.
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reported that reference standards were
blinded to the nNO measurements. There
was no major concern regarding the
technical aspects of the reference standard
testing, except in one cohort study in which
39.4% patients (56 of 142) were left
undiagnosed because of inconclusive
reference standard results (29). The
remaining 86 patients with conclusive
reference standard testing were included in
our meta-analysis.
Flow and timing (risk of
bias). Differential verification (EM or
genetic testing was performed only in
patients with PCD and not in control
subjects) and absence of simultaneous
testing (index and reference tests were
performed sequentially instead of
simultaneously) were frequent, especially in
case–control studies. Both of these factors
may artificially increase sensitivity and
specificity.
Data Synthesis
When we pooled the results of 12 studies, we
observed that the bivariate analysis (average
sensitivity and specificity for all thresholds)
showed a summary sensitivity of 97.6%
(92.7–99.2) and specificity of 96.0% (87.9–
98.7), as well as a positive likelihood ratio of
24.3 (7.6–76.9), a negative likelihood ratio
of 0.03 (0.01–0.08), and a diagnostic odds
ratio of 956.8 (141.2–6481.5), for nNO
measurements. For this analysis, isolated
IDA defects were reclassified as non-PCD
when feasible. Assuming a pretest
probability of 35% (17, 18, 29, 31, 33),
corresponding positive and negative
predictive values were 92.9% (80.5–97.6)
and 98.7% (95.7–99.6), respectively
(Appendix E3). A forest plot presenting
studies in ascending order of thresholds is
presented in Figure 3. A summary
hierarchical receiver operating
characteristic curve illustrating how
sensitivity and specificity traded off with
each other as thresholds varied is presented
in Figure 4.
Heterogeneity
Subgroup analysis. Sources of heterogeneity
were explored using subgroup analyses.
Studies presenting a lower risk of bias in
different domains (e.g., using cohort-type
design, disease control subjects over healthy
control subjects, and prespecified nNO
cutoff values) showed slightly lower
diagnostic test accuracy. Interestingly,
studies that systematically excluded CF
prior to PCD testing (15, 17, 30, 31, 33)
showed a slightly higher diagnostic
accuracy than studies that did not exclude
CF (14, 29, 31, 32, 34, 35) (sensitivity of
Santamaria 2008
Study
Beydon 2015
Boon 2014
Harris 2014
Leigh 2013 (lead site)
Leigh 2013 (other sites)
Mateos Coral 2011
Noone 2004
Papon 2012
Piacentini 2008
Pifferi 2011
Wodehouse 2003
TP FP FN TN Cut-off Sensitivity (95% CI)
13 1 0 14 17.0 1.00 [0.75, 1.00]
1.00 [0.63, 1.00]
1.00 [0.72, 1.00]
1.00 [0.88, 1.00]
1.00 [0.83, 1.00]
0.99 [0.96, 1.00]
0.99 [0.92, 1.00]
0.91 [0.79, 0.98]
0.89 [0.75, 0.97]
0.75 [0.59, 0.87]
0.99 [0.92, 1.00]
0.92 [0.64, 1.00]
Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI)
0.93 [0.68, 1.00]
1.00 [0.87, 1.00]
0.97 [0.83, 1.00]
0.85 [0.75, 0.92]
1.00 [0.89, 1.00]
1.00 [0.98, 1.00]
0.75 [0.64, 0.84]
0.86 [0.68, 0.96]
0.93 [0.87, 0.97]
0.90 [0.84, 0.95]
1.00 [0.95, 1.00]
0.71 [0.48, 0.89]
8 0 0 27 20.0
11 1 0 29 38.0
30 12 0 66 50.0
20 0 0 33 59.0
148 0 1 147 77.0
70 21 1 63 77.0
41 4 4 25 82.0
34 10 4 132 90.0
30 13 10 120 96.0
12 6 1 15 100.0
68 0 1 71 100.0
0.80.60.40.20 1 0.80.60.40.20 1
Figure 3. Forest plot (in ascending order of nasal nitric oxide cutoff value in nanoliters per minute). CI = confidence interval; FN = false negative; FP = false
positive; TN = true negative; TP = true positive.
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Figure 4. Hierarchical summary receiver operating characteristic curve (HSROC) for the 12 included
studies.
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97.7% vs. 95.1% and specificity of 98.5% vs.
91.4%, respectively).
Sensitivity analysis. The most relevant
source of heterogeneity was the strategy
used for the reference standard of PCD
disease (EM alone vs. extended reference
standard combining EM and/or genetic
testing). Thus, we performed a sensitivity
analysis including only the seven studies
with the extended reference standard of EM
defects and/or genetic diagnoses (14–17, 29,
30, 33), which included 1,086 patients
(430 patients with PCD, 656 patients
without PCD). Globally, these seven studies
were at lower risk of bias than the whole
group (Figure 5), with proportionally
more cohort-type studies, less using
asymptomatic patients as their control
group, and more studies prespecifying their
nNO cutoff. Pooled analysis showed a
summary sensitivity of 96.3% (88.7–98.9)
and specificity of 96.4% (85.1–99.2), as
well as a positive likelihood ratio of 26.5
(5.9–119.1), a negative likelihood ratio
of 0.04 (0.01–0.12), and a diagnostic odds
ratio of 699.3 (67.4–7,255.9), when we
compared nNO with the extended reference
standard of EM defects and/or biallelic
genetic mutations (Figure 6). According
to Grading of Recommendations
Assessment, Development, and Evaluation
methodology, the overall certainty of
evidence was moderate when we evaluated
studies comparing nNO with an extended
reference standard of EM and/or genetics
(see Table 3 ).
Discussion
In this meta-analysis, the diagnostic testing
accuracy of nNO is excellent when
compared with EM, and only slightly lower
when compared with the extended reference
standard of EM and/or genetic testing. Both
EM and genetic analysis are imperfect
reference standard PCD tests, with currently
estimated sensitivity at 0.70 (3, 37), and
each of these detecting PCD cases that can
be missed by the other test. Additionally,
these reference standard tests can
frequently provide nondiagnostic results,
with up to 40% of clinical biopsies showing
inadequate cilia for EM analysis (38) and
up to 43% of genetic testing detecting
monoallelic mutations or variants of
unknown significance (39). Conversely,
nNO measurement is a highly feasible test
in cooperative patients (generally .5 yr
old), with successful measurements
accomplished in more than 90% of patients
in this meta-analysis. Although nNO
testing has largely been considered as a
PCD screening test, this analysis shows that
nNO has a diagnostic potential similar to
the accepted confirmatory PCD tests of EM
and genetic analysis. Thus, in populations
with an appropriate clinical phenotype
for PCD, where CF is ruled out, nNO
measurement is a comparable PCD
diagnostic test, with the added benefits of
being highly feasible, painless, noninvasive,
FLOW AND TIMING
REFERENCE STANDARD
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80%60%
Proportion of studies with low, high or unclear
RISK of BIAS
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Figure 5. Assessment of validity of individual studies with Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 tool for the seven included
studies comparing nasal nitric oxide to an extended reference standard of electron microscopy and/or genetics. The QUADAS-2 tool is designed to
assess the quality of primary diagnostic accuracy studies and consists of four key domains evaluating the methods used with regard to patient selection,
index test, reference standard, and flow of patients through the study, as well as timing of the index test and reference standard. The results presented
show that the 7 selected studies were at lower risk of bias and concern regarding applicability than the initial 12 analyzed studies presented in Figure 2.
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rapid, and relatively inexpensive (U.S.$25–
U.S.$85) for patients. However, there
are limitations to nNO testing for
PCD, including high purchase cost of
chemiluminescence machines, training of
device operators, lack of clinical approval
for nNO devices in the United States,
and the inability to rigorously test
uncooperative children (generally ,5 yr
old).
Disease prevalence influences posttest
probability, and this analysis assumes a PCD
disease prevalence of 35%, as demonstrated
when PCD is strongly suspected because of
the presence of a highly suggestive clinical
phenotype (18). This robust phenotype is
highly predictive of PCD on the basis of (1)
unexplained neonatal respiratory distress
at term birth, (2) year-round wet cough
starting before 6 months of age, (3) year-
round nasal congestion starting before
6 months of age, and (4) organ laterality
defects. Although some of the studies
included in this meta-analysis did not use
these specific symptoms to select candidates
for PCD diagnostic testing, most studies
included variations of these clinical criteria.
Thus, in a preselected population
expressing these PCD-specific symptoms,
nNO measurement is a highly accurate
diagnostic test and can replace EM or
genetic testing. If the prevalence is lower
because of less stringent phenotype
screening, the positive predictive value will
be lower. For example, if the prevalence of
PCD is 10% in a less-selective group, the
positive predictive value of nNO testing for
PCD is considerably lower at 73%. At this
lower PCD prevalence, approximately one-
fourth of patients with a positive nNO test
will not have PCD upon confirmatory
testing. Therefore, it is critical that careful
selection of patients for diagnostic
evaluation by nNO testing be
accomplished. Otherwise, in less-enriched
groups, nNO will be more useful as a triage
test prior to PCD diagnostic testing, as
opposed to a replacement diagnostic test.
Clinicians must consider this point and
appropriately screen patients for PCD-
specific clinical criteria before embarking
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Figure 6. Hierarchical summary receiver operating characteristic curve (HSROC) for the seven
studies comparing nasal nitric oxide to an extended reference standard of electron microscopy
and/or genetics.
Table 3. Summary of findings, including the seven studies comparing nasal nitric oxide with an extended reference standard of
electron microscopy and/or genetics*
Outcome Studies (n),
Patients (n)
Study
Design
Factors That May Decrease Quality of Evidence Effect per 100
Patients Tested
(Pretest Probability
of 35%)
Test accuracy
QoE
Importance
Risk
of Bias
Indirectness Inconsistency Imprecision Publication
Bias
True positives (patients
with PCD)
7 studies,
423
patients
Cohort and
case–control-
type studies
Serious† Not serious Not serious‡ Not serious None 34 (31–35) ÅÅÅ◯MODERATE Critical
False negatives (patients
incorrectly classified as not
having PCD)
1 (0–4) Critical
True negatives (patients
without PCD)
7 studies,
636
patients
Cohort and
case–control
studies
Serious† Not serious Not serious‡ Not serious None 63 (55–64) ÅÅÅ◯MODERATE Critical
False positives (patients
incorrectly classified as
having PCD)
2 (1–10) Important
Inconclusive 7 studies,
27 patients
— — — — — — — Important
Definition of abbreviations: PCD = primary ciliary dyskinesia; QOE = quality of evidence.
*Sensitivity, 0.96 (95% confidence interval, 0.89–0.99); specificity, 0.96 (95% confidence interval, 0.85–0.99); prevalence 35%.
†Four studies were case–control studies, among which one study included only healthy patients in the control group. Two studies did not prespecify the
nasal nitric oxide cutoff before performing measurements and were not blinded to the reference standard.
‡Not downgraded for inconsistency since the residual heterogeneity was explained by the difference in the risk of bias between studies.
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on PCD diagnostic investigations, including
nNO testing.
Two past meta-analyses have shown
findings similar to those of this analysis,
but neither publication used an extended
reference standard incorporating genetic
testing (7, 8). Rather, included studies used
varying combinations of different reference
standards, including clinical phenotype,
HSVA, EM, and rarely genetics. Our analysis
used rigorous criteria to define reference
standard testing. By contacting authors, we
eliminated studies with greater than or equal
to 30% isolated IDA defects and assigned
greater bias to studies with 20 to 30%
isolated IDA defects, because 25% of isolated
IDA defects resolve on repeat EM testing
(20). Through author communication,
we also significantly increased reference
standard data on genetic testing, which
improves the generalizability of this
analysis to current clinical practices in
North America, where genetic testing is
increasingly used in PCD diagnosis. Last, we
discovered that some studies performed EM
testing only if HSVA was first abnormal
and often did not repeat HSVA studies on
separate occasions or after cell culture.
Altogether, our rigorous definition of
reference standard testing greatly increases
the strength of this meta-analysis.
In this analysis, we also used meticulous
criteria to define the index test of nNO
measurement. We restricted analysis to studies
using chemiluminescence technology because
only this technology is recommended for nNO
measurement in PCD (40). Next, we limited
our data to nNO testing only through velum
closure techniques. Although tidal breathing
nNO measurements are of clinical value in
young children, PCD diagnostic cutoff values
have not been defined for these techniques.
Last, we excluded all patients with CF, who
can have nNO levels below PCD cutoff values,
which could affect diagnostic accuracy.
Even with our robust inclusion and
exclusion criteria, this analysis has some
limitations. First, despite its increasing clinical
recognition, PCD is still a relatively rare
disease, and our patient numbers are limited.
Second, the heterogeneity of PCD reference
standards poses difficulties for study
generalizability. Ciliary EM alone identifies
more classic cases of PCD, but itmisses variant
forms (41). The expense of genetic testing
also creates differential verification whereby
reference genetic testing is performed mainly
in patients with suspected PCD and not
in healthy control subjects, which affects
diagnostic testing accuracy. Nonsimultaneous
PCD diagnostic testing (using nNO as an
initial screening test, followed by EM and/or
genetic testing) may also have affected
diagnostic accuracy in the selected studies,
although blinding of researchers should have
minimized these effects. Owing to the rapid
discovery of novel PCD-causing gene
mutations, most genetic panels are
incomplete by the time of study publication,
which further decreases the diagnostic
accuracy of PCD genetic testing. However,
with future discovery of novel PCD genes that
result in normal ultrastructure with low nNO
levels, the false-positive rate of nNO testing
may decrease, and diagnostic accuracy may
actually improve. Last, studies in this analysis
using EM alone as the reference standard
were more often designed as case–control
studies, did not prespecify diagnostic nNO
cutoff values, or were not blinded to nNO
results during reference standard testing.
Each of these factors is associated with an
overestimation of diagnostic testing accuracy.
Thus, although it is possible that nNO testing
is actually less accurate when using an
extended reference standard of EM and/or
genetics, it seems more likely that studies
using EM alone as the reference standard are
at higher risk of bias, resulting in falsely
increased diagnostic testing accuracy.
Conclusions
nNO is a sensitive and specific test for
diagnosing PCD in cooperative patients
(generally .5 yr old), in whom CF has
been ruled out, and who have a robust
clinical phenotype for PCD. The reference
standard tests of EM and/or genetic
analysis are imperfect tests because both
lack sensitivity for PCD diagnosis.
Although nNO was previously considered
a PCD screening test, with a moderate
level of evidence, this meta-analysis
confirms that nNO testing has at least
equivalent and likely better diagnostic
testing accuracy than EM and/or genetic
testing for PCD. Thus, we propose that
nNO be considered a diagnostic test rather
than a screening test in this population.
Physicians must realize that normal nNO
levels do not rule out PCD, and patients
with highly compatible PCD clinical
phenotypes but normal nNO levels should
be subjected to further testing. In addition,
even in individuals with a compatible
clinical phenotype and low nNO,
confirmatory testing with EM or genetics
will yield additional diagnostic
information. As more genetic causes of
PCD are discovered, repeat meta-analysis
will be required to evaluate the diagnostic
testing accuracy of nNO measurement,
and the upcoming American Thoracic
Society–sponsored clinical practice
guidelines on PCD diagnosis will further
elaborate the accuracy of other PCD
diagnostic tests. Future study of tidal
breathing nNO measurement is needed
to evaluate the usefulness of this
noninvasive, rapid, and inexpensive
test for successful PCD diagnosis in
uncooperative children younger than
5 years old. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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